ADVANZ PHARMA (CXRXF) News Today $17.06 0.00 (0.00%) As of 06/10/2021 Add Compare Share Share Headlines Stock AnalysisBuy This Stock CXRXF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period PHAT Phathom Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comDimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trialMarch 12, 2024 | msn.comInterim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024February 27, 2024 | msn.comDimerix receives $10.7 million upfront payment from Advanz PharmaNovember 7, 2023 | msn.comApplied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetJanuary 4, 2023 | msn.comMADE in America Act is critical for the pharmaceutical industrySeptember 27, 2022 | dallasnews.comDPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeAugust 5, 2022 | seekingalpha.comIntercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.July 1, 2022 | benzinga.comIntercept Pharma to sell ex-U.S. rights for Ocaliva to Advanz PharmaMay 5, 2022 | seekingalpha.com Get ADVANZ PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter. Email Address CXRXF Media Mentions By Week CXRXF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CXRXF News Sentiment▼0.000.75▲Average Medical News Sentiment CXRXF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CXRXF Articles This Week▼00▲CXRXF Articles Average Week Get ADVANZ PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Protagonist Therapeutics News Ascentage Pharma Group International News HUTCHMED News Indivior News Apellis Pharmaceuticals News MorphoSys News Kymera Therapeutics News Ultragenyx Pharmaceutical News Immunovant News Alvotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CXRXF) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ADVANZ PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access